Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy

Table 3 ORs and 95 % CIs for selected NHL histological types by HCV RNA/HBsAg positivity. Italy, 1999–2014

	All^c	HCV-RNA⁺		All^d	HBsAg⁺
	N	N (%)	OR (95 % CI)^a,e	N	N (%)	OR (95 % CI)^a,f
Controls	1002	35 (3.5)	1^b	997	17 (1.7)	1^b
NHL cases	569	63 (11.1)		570	21 (3.7)
B-cell lymphomas	512	60 (11.7)	3.71 (2.37–5.81)	513	20 (3.9)	2.11 (1.07–4.15)
DLBCL	289	37 (12.8)	4.08 (2.46–6.76)	290	15 (5.2)	2.69 (1.30–5.59)
Burkitt	14	2 (14.3)	4.36 (0.82–23.26)	14	0 (0.0)
Follicular	103	1 (1.0)	0.38 (0.05–2.85)	103	4 (3.9)	1.96 (0.61–6.29)
Mantle cell	14	0 (0.0)		14	0 (0.0)
Marginal zone	33	9 (27.3)	8.62 (3.43–21.69)	33	0 (0.0)
Lymphoplasmacytic	14	4 (28.6)	8.43 (2.26–31.52)	14	0 (0.0)
Other B-cell lymphomas	10	0 (0.0)		10	0 (0.0)
SLL/CLL	35	7 (20.0)	7. 96 (2.95–21.48)	35	1 (2.9)	1.18 (0.14–10.05)
T-cell lymphomas	37	2 (5.4)	1.68 (0.37–7.69)	37	0 (0.0)
Other	2	0 (0.0)		2	0 (0.0)
NOS	18	1 (5.6)	1.73 (0.20–15.01)	18	1 (5.5)	2.58 (0.28–23.84)

NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval, DLBCL diffuse large B-cell lymphoma, SLL small lymphocytic lymphoma, CLL chronic lymphocytic leukemia, NOS not otherwise specified; ^aEstimated using unconditional logistic regression models adjusted for gender, age, study center, years of education, and place of birth; ^bReference category. ^cCases and controls with positive anti-HCV test and without available information on HCV-RNA were excluded; ^dCases and controls without available information on HBV markers were excluded; ^eReference category was anti-HCV^-; ^fReference category was HBsAg^-/anti-HBs^-/anti-HBc^-

ISSN: 1750-9378